Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hematologic Neoplasms clinical trials
Every US clinical trial registered for Hematologic Neoplasms — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
21 US clinical trials · 7 currently recruiting
The research picture
Hematologic Neoplasms has 21 registered US clinical trials, 7 of them open to new participants right now — about 33% of the total.
- 7
- recruiting participants now
- 33%
- of trials open to enrollment
- 1
- in Phase 3–4 (later-stage)
- 4
- top sponsor: National Cancer Institute (NCI)
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
UWCCC Molecular Tumor Board Registry
University of Wisconsin, Madison
NCT03023202
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
National Heart, Lung, and Blood Institute (NHLBI)
NCT00071045
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Mayo Clinic
NCT02958462
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
National Cancer Institute (NCI)
NCT05327023
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
National Cancer Institute (NCI)
NCT04959175
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
National Cancer Institute (NCI)
NCT07162038
Cognitive Training Intervention and Attitudes Towards Genetics
University of Alabama at Birmingham
NCT03094026
Optimizing PTCy Dose and Timing
National Cancer Institute (NCI)
NCT03983850
Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
Ronald Paquette
NCT05256537
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
NCT02477878
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
Nucleix
NCT04264767
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
Hoffmann-La Roche
NCT00623870
Comprehensive Frailty Assessment
Ohio State University Comprehensive Cancer Center
NCT02033928
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
Augusta University
NCT02635984
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
Washington University School of Medicine
NCT00914849
Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
Jazz Pharmaceuticals
NCT00389428
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
Dimitrios Tzachanis, MD PhD
NCT03680092
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
University of Michigan Rogel Cancer Center
NCT01790568
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
Northside Hospital
NCT01244906
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Esanex
NCT00595686
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
University of Arizona
NCT00997386
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Hematologic Neoplasms Trial Landscape
ClinicalTrials.gov lists 21 US studies indexed under Hematologic Neoplasms, and 7 of those are currently open to recruitment — roughly 33% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Hematologic Neoplasms shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 14 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Hematologic Neoplasms is led by National Cancer Institute (NCI) with 4 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 21 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Hematologic Neoplasms?
PlainTrial tracks 21 US clinical trials for Hematologic Neoplasms, of which 7 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Hematologic Neoplasms?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.